Clinical Trial Update: First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating first-line gemcitabine, cisplatin plus ipilimumab for metastatic urothelial carcinoma has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• CISPLATIN (cisplatin)
• Gemcitabine (Gemcitabine)
• ipilimumab (ipilimumab)

Snippet

Sponsor: Hoosier Cancer Research Network | Conditions: Urothelial Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2019-11-29